- Company
- Patents for representative DM drugs are expected to expire
- by Kim, Jin-Gu Dec 29, 2021 05:58am
- Next year, patents for DPP-4 inhibitor-based diabetes treatments such as Tenelia, Onglyza and Galvus will be released one after another. It is predicted that generic companies will join the domestic DPP-4 inhibitor-affiliated diabetes treatment market, which has grown to 600 billion won a year. In the case of generics for Galvus, more than 10
- Company
- A reimbursed optn in hormone-sensitive prostate cancer?
- by Eo, Yun-Ho Dec 29, 2021 05:58am
- Whether a treatment option may be added to the hormone-sensitive metastatic prostate cancer treatment environment that lacked options is gaining attention. According to industry officials, Astellas Korea applied for the extended insurance benefit of its anticancer drug ‘Xtandi (enzalutamide)’ in combination with androgen deprivation the
- Policy
- Paxlovid is a new weapon added to our fight against COVID-19
- by Lee, Jeong-Hwan Dec 29, 2021 05:58am
- “An oral-type treatment will be prescribed to patients with severe or critical COVID-19 that are unsuitable to be treated with an injection-type (antiviral). In other words, we have secured another option in our armory to use against COVID-19.” Ministry of Food and Drug Safety Minister Gang-lip Kim This is what Minister Gang-lip
- Policy
- Gov-National Assembly introduce oral treatment for COVID-19
- by Lee, Jeong-Hwan Dec 29, 2021 05:57am
- As COVID-19 spreads to the Omicron mutation following the delta mutation, and the number of deaths and new confirmed patients increases, the attention of the National Assembly and the government is focusing on treatments.The National Assembly's Health and Welfare Committee is urging the U.S. FDA to preemptively secure domestic antibody treat
- Company
- LegoChem transfers candidate technology to British company
- by Chon, Seung-Hyun Dec 29, 2021 05:57am
- LegoChem Biosciences announced on the 27th that it has signed a technology transfer contract with Iksuda for joint development of a new anti-cancer drug candidate LCB14. The contract is worth up to $1 billion (about 1.2 trillion won). With this contract, LegoChem Biosciences secured $50 million (about 60 billion won) in advance payments and shor
- Company
- SK Bioscience will complete major facilities in Songdo
- by Chon, Seung-Hyun Dec 28, 2021 05:51am
- SK Bioscience, the third-largest pharmaceutical bio company in market capitalization, will build a new construction in Songdo, Incheon. It will invest 300 billion won by 2024 to build a new factory and laboratory. Along with Samsung Biologics, Celltrion, and Celltrion Healthcare, the first to fourth place in the pharmaceutical bio market will ga
- Policy
- Entry of FDA-approved new Chinese blood cancer drug imminent
- by Lee, Tak-Sun Dec 28, 2021 05:51am
- A new blood cancer treatment that was developed by a Chinese pharmaceutical company and approved by the US FDA will be soon introduced to Korea. The drug awaiting entry is BeiGene Korea’s ‘Brukinsa.’ If approved, Brukinsa will be the second new drug approved by a Chinese pharmaceutical company following Antengene’s ‘Xpovio tab 20mg.
- Policy
- MFDS approves emergency use of Pfizer’s oral COVID-19 drug
- by Lee, Tak-Sun Dec 28, 2021 05:50am
- Pfizer’s oral COVID-19 treatment ‘Paxlovid’ received emergency use authorization in Korea as well. Authorities plan to use the drug to treat adults and pediatric patients over the age of 12 with mild-to-moderate COVID-19 at high risk of progressing to severe disease. Pharmacies will be supplying the pills for patients treated from thei
- Company
- ST Pharm has applied for phase 1 of the COVID-19 vaccine
- by Kim, Jin-Gu Dec 28, 2021 05:50am
- ST Pharm will join the ranks of COVID-19 vaccine development. It introduced mRNA vaccine platforms such as Pfizer and Moderna vaccines. ST Pharm announced on the 24th that it has applied for a phase 1 clinical trial plan for the mRNA-based COVID-19 prevention vaccine STP-2104 to the MFDS. Clinical trials were planned in stages of capaci
- Company
- Ildong's new DM GLP-1 analog has acquired a new patent
- by Dec 28, 2021 05:49am
- Ildong (CEO Yoon Woong-seop) announced on the 24th that it has obtained a patent for domestic substances for ID110521156, a new drug candidate for type 2 diabetes treatment under development. &8203; ID110521156 is a drug in the GLP-1 receptor agonist family that acts as a analog to the Glucagon-like peptide-1 (GLP-1) hormone that regulates
